Capital International Investors Intellia Therapeutics, Inc. Call Options Transaction History
Capital International Investors
- $488 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
339Shares Held
98.3MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$154 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$127 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$114 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$53.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$45 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $899M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...